T cell therapies, such as CAR-T therapies, are rapidly emerging as a powerful new treatment and potential cure for cancer. Understanding the optimal conditions to cryopreserve T cells is an important step towards developing better processes and better T cell therapies.
In this webinar, we will help you learn better strategies for cryopreserving leukapheresis material for T cell processing, and how to extend leukopak stability for added flexibility in manufacturing T cell therapies.
We will also present data on finding the right balance between excipients and cryoprotectants during drug product formulation, while exploring how formulation can affect the phenotype and function of the T cell product.